|

Determining Minimal Residual Disease Using ctDNA Deep Sequencing

RECRUITINGN/ASponsored by Masaryk Memorial Cancer Institute
Actively Recruiting
PhaseN/A
SponsorMasaryk Memorial Cancer Institute
Started2022-08-22
Est. completion2026-12-31
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07660627

Summary

Preoperative neoadjuvant chemotherapy is the standard treatment for locally advanced gastrointestinal tumours. However, not all patients respond to preoperative treatment. Early identification of progression during neoadjuvant chemotherapy or diagnosis of early disease relapse during adjuvant treatment is essential to modify the treatment strategy. The aim of this project is to validate ctDNA as a biomarker of molecular relapse/progression of disease.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Consent to participate in the study
* Patients with esophageal, gastric, or pancreatic cancer, stage 0-2
* Patients with locally advanced, potentially operable disease treated with systemic perioperative chemotherapy or chemoradiotherapy
* Patients with metastatic disease treated with first- to third-line palliative systemic therapy

Exclusion Criteria:

* not specified

Conditions4

CancerEsophageal AdenocarcinomaGastric CancerPancreatic Cancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.